SureTrader
Home > Boards > US Listed > Biotechs >

Avid Bioservices Inc. (CDMO)

CDMO RSS Feed
Add CDMO Price Alert      Hide Sticky   Hide Intro
Moderator: TekNuLoof, cjgaddy, keep_trying, north40000, biopharm, 4OurRetirement
Search This Board: 
Last Post: 1/21/2018 11:02:00 PM - Followers: 851 - Board type: Free - Posts Today: 0


Avid Bioservices, Inc. (Nasdaq “CDMO”), Tustin CA. http://www.avidbio.com

Avid Bioservices is a CDMO committed to improving the lives of patients by manufacturing products derived from mammalian cell culture for the biotechnology & biopharmaceutical industries. Services include cGMP clinical & commercial product manufacturing, purification, bulk packaging, stability testing & regulatory strategy, submission, and support. The company also provides a variety of process development activities, including cell line development & optimization, cell culture & feed optimization, analytical methods development, and product characterization.


DEC. 2017 Company Update - "Peregrine is Transitioning to a Pure-Play CDMO, Avid Bioservices, Inc."
12-11-17 10-Q for q/e 10-31-17:
Business Description – Peregrine is a company committed to improving the lives of patients by manufacturing pharmaceutical products through our CDMO, Avid Bioservices, Inc.
"Over the next 60 days, we plan to complete the transition from a R&D company to a dedicated CDMO company focused on dev. & mfg. of biopharmaceutical products derived from mammalian cell culture.
We plan to take ADDL. STEPS steps over the near term, including but not limited to:
1. Rebranding the company as Avid Bioservices, Inc.
2. Changing our ticker symbol on the NASDAQ Capital Market to align with our rebranding efforts
3. Broadening our sales force
4. Increasing our marketing efforts to support our rebranding & vision
5. Completing the wind down of all R&D activities and the potential licensing/divestiture of our assets related to our R&D operations.”
12-26-17: Roger Lias replaces Steven King as Pres./CEO; in process of changing name to Avid Bio. and new Nasdaq Ticker https://tinyurl.com/yb34e2t8
1-8-17: Name chgs. to Avid Bioservices, Inc. (from Peregrine Pharm.) and NASDAQ Ticker chgs. to "CMDO" (Preferred: CDMOP) https://tinyurl.com/y8vhjow4

Quotes: Yahoo: Yahoo.com/CDMO Nasdaq: http://www.nasdaq.com/symbol/cdmo RT: http://www.nasdaq.com/symbol/cdmo/real-time
IR: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com, Tim Brons (Media) 415-675-7402 tbrons@vidasp.com

UPCOMING EVENTS: http://ir.avidbio.com/events.cfm

Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - PR & CC Transcript: https://tinyurl.com/ybycb2s6
Jan8/3:30pm/Roger Lias: EBD's Biotech Showcase 2018 (parallel w/JPM Conf.), SanFran https://ebdgroup.knect365.com/biotech-showcase Corp. Presentation

Jan18: Avid Bioservices' 2017 Annual Shareholder’s Mtg – 11-13-17/PR: http://tinyurl.com/y9tdcob5 VotingRecDate=11-27-17
…10amPT at Avid’s Myford Facility, 14191 Myford Road, Tustin, CA 72780 http://ir.avidbio.com/events.cfm
Webcast https://edge.media-server.com/m6/p/ij9i8ypx
...PROXY/14A: https://tinyurl.com/y7qprpg9 =>Vote here: https://www.proxyvote.com


SEC:
Latest 10K 4-30-17 iss. 7-14-17 http://tinyurl.com/ycxu4l5n PR: http://tinyurl.com/yb4wulvu (Cash 4-30-17=$46.8mm); Amended 8-25-17: http://tinyurl.com/yb5jq7vc
Latest 10Q 10-31-17 iss. 12-11-17 https://tinyurl.com/y75kwojs PR: https://tinyurl.com/ybycb2s6 (Cash 10-31-17=$27.7mm)
ALL SEC filings for CDMO: https://tinyurl.com/yc4zjyzv
CDMO's Corp. Bylaws (a/o 11-14-14): http://tinyurl.com/y8hsppea
Poison Pill adopted 3-16-06: http://tinyurl.com/yvypvh - 44-pg SEC filing: http://tinyurl.com/5m57ut BUNGLER explains in plain language: http://tinyurl.com/mft4nd6
5-15-17: Parties Settle 2013 Shareholder Derivative CA Lawsuit vs. BOD(re: Fiduciary Duties) http://tinyurl.com/y982h3rt
...7-27-17: Final Settlement Hearing - transcript excerpts, comments by Judge J. Travis Laster: http://tinyurl.com/y9m6ee59
SHARES: 
Shares O/S as of 12-6-17=45,212,760 - history since 4-2006: https://tinyurl.com/y76cbyt5
...A/O 10-31-17: 39,040 warrants o/s with wgt.avg. exercise price of $17.29 -- 4,123,054 stock options outstanding at a wgt.avg. exercise price of $8.96. (pg.14 10Q)
PPHM shares were 1:7 Reverse Split eff. 7-10-17 (315mm/$.606=>45mm/$4.24) http://tinyurl.com/ycohqn6j
**NOTE: PPHM shares were 1:5 Reverse Split eff. 10-19-09 (~237mm/$.64=>~47.4mm/$3.20) http://tinyurl.com/ykuw588
...4-12-17/8K: Nasdaq Delisting Notice($1 min.), 4-10-17 deadline missed; Peregrine to Appeal for Extension http://tinyurl.com/yagoqth5
...6-7-17/8K: Hearing Panel Grants Extension until 7-21-17 (must be over $1 by 7-7-17) http://tinyurl.com/yauwzhum

12-27-13: S-3 Registration, “up to $100,000,000”, Common & Preferred http://tinyurl.com/ky4ufth - S-3 cover: Michael A. Hedge (Leader, Life Sciences M&A team), K&L Gates LLP
...2-5-14: PPHM Announces Public Offering of 10.5% Series E Convertible Preferred Stock http://tinyurl.com/lkxsna6
...2-11-14: PPHM Raises net $16.2mm selling 700k Preferred Shares with 10.5% div. at $25/sh, convertible to common at $3/sh http://tinyurl.com/jwmsnsk (8-K)
...6/14/14-7/14/13: PPHM Raises net $9.5mm selling 400k Preferred Shares with 10.5% div. at $25/sh, convertible to common at $3/sh http://tinyurl.com/mhva3k3 (4-30-14 10-K pg. F-34; $20mm gross remaining)
...6-30-14: SABBY MGT. (led by Hal Mintz) holds 291600/PPHMP a/o 6-30-14 ($7.0mm@1.66/sh. common): http://tinyurl.com/kxezbsf
...4-13-14: PPHM Registers $30mm of 10.50% Series E Convertible Preferred Stock and $25mm ATM Common Stock in 2 424B5’s: http://tinyurl.com/lth28zj & http://tinyurl.com/kpjloar
...12-23-14: S-3 Registration, “up to $150,000,000”, Common & Preferred http://tinyurl.com/nhfr55a

A-T-M (At-The-Market) Sales 3/2009 - 7/14/17 ($272,500,000gr./34,869,747sh=$7.81/sh): http://tinyurl.com/yagmu2on

...12-29-10: ATM Agreement (up to $75mm) with MLV filed - 8K: http://tinyurl.com/2a6w76g
...3-9-12: PPHM files shelf to sell up to $150mm common stock, warrants, S3: http://tinyurl.com/7dl7pjm
...12-28-12: New ATM Agreement (up to $75mm) with MLV filed - 424B5: http://tinyurl.com/ayny2b3
…6-13-14: New ATM Agreement (up to $25mm) with MLV filed - 424B5: http://tinyurl.com/ycxje6pj
…8-7-15: New ATM Agreement (up to $20mm) with NOBLE filed - 424B5: http://tinyurl.com/q9zvw6n
…8-7-15: New ATM Agreement (up to $30mm) with MLV filed - 424B5: http://tinyurl.com/oc53ugn
...7-14-17: ALL Existing ATM's are fully exhausted - cannot do anymore until a new one is opened (and reported via 424B5), against the $67mm remaining on the orig. $150mm shelf filed 4-23-14/S-3.
INSIDER-Trans: http://tinyurl.com/ypkow8 & http://tinyurl.com/2yvlj4
Inst. Holdings (Nasdaq.com) - updated qtly, 45-days after each q/e cutoff: http://www.nasdaq.com/symbol/cdmo/institutional-holdings
Short Interest, upd. twice a month: http://tinyurl.com/552p6n ...Updates 1 day earlier: http://tinyurl.com/292xyd
Director Eric Swartz's Jan-Feb'10 Buying Streak, 100k@$3.12preR/S = 14.3k@$21.84/sh: http://tinyurl.com/yegxpvu
9-8-11: Roth arranges direct sale of 893,179sh.@$7.77 to 3 inst's, net=$6.5mm http://tinyurl.com/3otm3t5


11-15-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Roger Farley+Stephen White) now owns 9.6% stake (4,325,889sh.) in PPHM
FULL HISTORY of PPHM-Ronin PR’s, Letters, 13-D’s, Form4’s, Proxy’s, etc: https://tinyurl.com/ycb3fpfm
...4,173,391 COMMON - 9.2% of 45,212,760 common O/S at 12-6-17 (total beneficial=4,325,889 if Pref. conv. x1.1905 to Common)
...128,099 PREFERRED – 7.8% of 1,647,760 preferred O/S at 11-27-17

......As a Group, ie, “people that share the furtherance of a common objective/concerted action”; 13D’s are reserved for ACTIVE INVESTORS who may be “interested in agitating for some kind of a change at the company”.
...1-8-17: Name chgs. to Avid Bioservices, Inc. (from Peregrine Pharm.) and NASDAQ Ticker chgs. to "CMDO" (Preferred: CDMOP) https://tinyurl.com/y8vhjow4
...12-26-17: Roger Lias replaces Steven King as Pres./CEO; in process of changing name to Avid Bio. and new Nasdaq Ticker https://tinyurl.com/yb34e2t8
...11-28-17: PPHM+RONIN Settle - Reconstituted 7-Member BOD (Johnson/Swartz/Pohl/King resign) https://tinyurl.com/y7g72zh4
......Full Agreement(8-K): Header: https://tinyurl.com/y8m35nax Complete Agreement: https://tinyurl.com/y7b3gkc2 PROXY/12-7-17: https://tinyurl.com/y7qprpg9
......Profiles of all 7 BOD members & Compensation as of 11-28-17: https://tinyurl.com/y9lkl4q2
.......(Joseph Carleone/Chair, Richard Hancock, Gregory Sargen, Joel McComb, Roger Lias, Mark Bamforth, Patrick Walsh)

...10-30-17: RONIN/SW-Invest issues 30-pg. PDF Presentation, “Shareholders Seeking Change” http://tinyurl.com/yc88aonq
...10-10-17: RONIN/SW-Invest PR adding 4th BOD Nominee (James Egan) and ups stakes 8.8%=>8.9% http://tinyurl.com/ya8fgsr7

...8-29-17: RONIN/SW-Invest PRELIM. Proxy Statement (14A) http://tinyurl.com/yay55u3p - includes 35-pt. chronology of events (1-17-17 thru 8-14-17) & all Ronin/SW PPHM stock trans.
...8-14-17: Ronin/SW-Invest PR commenting on PPHM's 8-11-17 PR (laying off 20% employees) http://tinyurl.com/y7hjryog
...7-20-17: Ronin/SW-Invest Letter to Employees of Peregrine; PPHM Comments http://tinyurl.com/yb6ds27s
...7-13-17: Ronin/SW-Invest Letter to Stockholders; PPHM Comments http://tinyurl.com/ybr8ycbp - Ronin nominates Gregory Sargen, Brian Scanlan, Saiid Zarrabian for election to PPHM's board at next ASM ~10-12-17.


10-30-15: Kenneth Dart (Eastern Capital) acquires 9.5% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON - 8.4% of 45,212,760 common O/S at 12-6-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.6%)
...440,000 PREFERRED - 26.7% of 1,647,760 preferred O/S at 11-27-17
...…...9-29-17/Form4: http://tinyurl.com/y9oadloa <=No chg. in Ownership; has had <10% stake for many months due to dilution. ??


Plus, INSTITUTIONS a/o *9-30-17: 9,536,290sh. = 21.1% (of 45,212,760) <=*incl. Tappan’s 11-13-17/13G
...8,491,679 + 1,044,611(Tappan adds after 9-30-17) = 9,536,290
http://www.nasdaq.com/symbol/cdmo/institutional-holdings
...TOTAL Large Shareholders: Ronin(4,325,889) + EastCap/Dart(4,300,992) + INST(9,536,290) = 18,163,171shs., 40.2% of 45,212,760 O/S at 12-6-17.
TOP13:
Tappan Street (Prasad Phatak) 3,915,611 +2,259,359 <=per 11-13-17/13G http://tinyurl.com/y85pz4fs
Vanguard Group                1,518,110   +488,355
Blackrock (Larry Fink)          761,302    -44,720
Bandera Partners                555,000   +351,996
Renaissance Technologies        547,190    +66,030
Geode Capital Mgt.              225,676         -3
Fondren Mgt.                    205,000        NEW
Stifel Financial                204,305   +200,762
Eqis Capital Mgt.               143,595     -6,804
Wells Fargo & Co.               117,829    +69,488
Connor Clark & Lunn              98,772        NEW
Brown Advisory Sec.              82,858         -1
Pdt Partners                     82,800        NEW
And this big Q3 drop:
#18 Kennedy Capital Mgt.         69,820 -1,324,246


ANALYST COVERAGE:
Noble Life Science Partners/Caroline Palomeque https://noblecapitalmarkets.com/life-science (init. 7-16-15); 12-12-17: Buy/PT=$10.00

AVID BIOSERVICES, Inc.: http://www.avidbio.com
12-11-17: PPHM's Revs & Burns By Qtr Table, FY07/Q1 thru FY18/Q2 (q/e 10-31-17): https://tinyurl.com/ybycb2s6 (since 5-2006: Avid=$271.1mm, Total=$297.7mm, incl.Govt)
......Avid FY18 (fye 4-30-18) revs guidance: $50-55mm; committed backlog=$33mm.
11-29-17: Tracy L. Kinjerski (ex-CMC Biologics) joins Avid as VP/Bus.Operations https://tinyurl.com/yc4zenkc
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s President and join PPHM’s BOD eff. 9-25-17 https://tinyurl.com/yddufw4s
7-14-17: Avid Scientists develop “Antibody Discovery & Characterization Platform (TM: EnAbl)” http://tinyurl.com/ydhdde8p
...S.King: “through which we can generate antibodies against virtually any target. These capabilities are state-of-the-art and meant for rapid screening for high affinity antibodies as drug candidates.”

5-2017: Avid II (Myford) adds 2 MilliporeSigma Mobius 2,000L single-use bioreactors; total mfg. capacity now ">11,000L". http://tinyurl.com/ky7bmu4
5-10-17: Halozyme comments on Avid II(Myford) expansion in their 3-31-17/10Q pub. 5-9-17: http://tinyurl.com/mrl34uk
..."validation of the new facility is scheduled to end in Q2/2017… Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20.”
2-28-17: Avid & Cook remain Halozyme's 2 CMO's (“working to scale-up/validate/qualify Avid II/Myford for Roche collab.”): http://tinyurl.com/h75teta
...9-19-2017: Catalent to acquire CDMO Cook Pharmica for $950M ($179M/sales x 5.3) http://tinyurl.com/yd46m8py
6-2-16: Corp.Update – Avid Expansion & Drug Development - http://tinyurl.com/zvmhqmr
5-23-16: Pete Gagnon (100pubs/presentations, 12+patents, 30 pending patents) Appointed VP/Process-Services of Avid http://tinyurl.com/hg6abdq – See Oct'15: https://www.youtube.com/watch?v=JqJIH33JY8g
3-7-16/Avid II: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs) http://tinyurl.com/za2j9mt
12-10-15/Avid II: Avid Expansion into MYFORD Facility now GMP-run ready (potential +$40mm sales) - contemplating further expansion http://tinyurl.com/z35623w
6-17-15: Avid’s John Haney (ex-Genentech/Pfizer) speaking at BIO-INTL’5/Philly http://tinyurl.com/pnlquu3 & http://tinyurl.com/nl4vbgk
...”Designing & Implementing Avid’s New State-of-the-Art Single-Use Facility for Late Ph.3 & Commercial Prod.” - SK: "We've seen tremendous interest for production in the new facility, both from new & existing clients"
12-10-14: Avid to Double Mfg. Capacity (“Myford Expansion”) http://tinyurl.com/mmc3qgy & http://tinyurl.com/kmdgq8t

3-24-15: Avid Receives CMO Leadership Awards for Its Commitment to Innovation & Reliability http://tinyurl.com/psep47f
3-12-13: Avid Q3'FY13 GP=$3.3mm; S.King 3-2012, "We have a profitable CMO, Avid Bioservices" http://tinyurl.com/l97rzm8
2-26-13: Avid Presents QbD/CPPs/CQAs at "BiopharmDev/Prod-Week"  http://tinyurl.com/cjzfh73
4-2-12 AACR'12: Avid presents New Mab-Eng. Process (Fc/ADCC), Client Proj. http://tinyurl.com/7yrwqm7 (see #2510)
6-14-10: Avid adds 'Line #4 FILL-FINISH' capability, CMOLocator.com http://tinyurl.com/3xgu3ox
5-3-10: PPHM leases addl. 11,000sq adjacent space (Avid exp?): http://tinyurl.com/327dk2j
9-21-09: Avid becomes sole U.S. W.Coast CMO in Boehringer Ingelheim's Global Prod. Alliance Network http://tinyurl.com/l9nf4n
11-10-08: Avid expands capacity by adding 100L & 1000L Hyclone bioreactors: http://tinyurl.com/69qgl5
6-25-08: Avid Selected as 1st U.S. CMO for DSM/Crucell's PER.C6 Cell Line: http://tinyurl.com/4geqxw
7-14-08: Avid is CMO for Arius Research's lead drug, "AR001 Targeting CD44": http://tinyurl.com/6hrwrt - 7-23-08 Roche buys Arius for $190mm  http://tinyurl.com/5fg6jd

COMPANY UPDATES & ARTICLES: [ CDMO News: http://finance.yahoo.com/q/h?s=PPHM ]
1-18-18: Peregrine's 2017 ASM (Avid/Myford, Tustin) ...PROXY/14A iss. 12-7-17: https://tinyurl.com/y7qprpg9
12-26-17: Roger Lias replaces Steven King as Pres./CEO; in process of changing name to Avid Bio. and new Nasdaq Ticker ("early 2018") https://tinyurl.com/yb34e2t8
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6

...Dr. Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
11-28-17: PPHM+RONIN Settle - Reconstituted 7-Member BOD (Johnson/Swartz/Pohl/King resign) https://tinyurl.com/y7g72zh4
...Full Agreement(8-K): Header: https://tinyurl.com/y8m35nax Complete Agreement: https://tinyurl.com/y7b3gkc2
...Profiles of all 7 BOD members & Compensation as of 11-28-17: https://tinyurl.com/y9lkl4q2
.....(Joseph Carleone/Chair, Richard Hancock, Gregory Sargen, Joel McComb, Roger Lias, Mark Bamforth, Patrick Walsh)

Sept-Nov2017 PPHM/Form4’s for reconstituted 7-person BOD (Options Awarded):
...Joseph Carleone (Chairman): 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Richard Hancock: 75,000 @4.67 vesting monthly over 3yrs beg. 12-27-17
...Gregory Sargen: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Joel McComb: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Patrick Walsh: 75,000 @4.08, vesting monthly over 3yrs beg. 11-20-17
...Mark Bamforth: 75,000 @3.88, vesting monthly over 3yrs beg. 11-17-17
...Roger Lias: 150,000 @3.19, vesting in 4 equal annual installments beg. 9-25-18
...OPEN MKT PUR: Mark Bamforth Buys 50,000sh. @$4.50 (open mkt) on 10-27-17 http://tinyurl.com/ya7pyyu5

11-15-17/Outsourcing-Pharma: “How This R&D Company (Peregrine) is Transitioning to a Pure-Play CDMO: ‘Opportunities Are Almost Endless’" - Recap of interviews with Steve King & Avid Pres. Roger Lias http://tinyurl.com/y7dv9faz
11-13-17/PR: Peregrine's 2017 ASM to be held 1/18/18 at Avid (VotingRecDate=11-27-17): http://tinyurl.com/y8b2rjkg
10-23-17/8-K: “Recently Amended” BOD Compensation Pgm http://tinyurl.com/y7mvg6wt  $55000/yr + $15000/committee + $2000/meeting
10-24-17: Peregrine Adds Patrick D. Walsh to BOD, "An Industry Veteran with 30+yrs Experience Leading Successful CDMO Org’s” http://tinyurl.com/ydxlv7sb
10-19-17: Peregrine Adds Mark R. Bamforth to BOD, "10yrs/Genzyme; 30yrs of biologics leadership experience, incl. founding 2 CDMOs" http://tinyurl.com/ydxlv7sb
...10-27-17/Form4: Mark Bamforth buys 50,000sh. @$4.50 (open mkt): http://tinyurl.com/ya7pyyu5
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s President and join PPHM’s BOD eff. 9-25-17 https://tinyurl.com/yddufw4s
9-11-17: Qtly. Conf. Call (King/Lias/Lytle) Transcript http://tinyurl.com/y9y8qdac
...CEO SK: “For this reason, we have concluded that in order to best position Peregrine’s R&D assets for successful development, they should be advanced by a partner with the appropriate expertise and ample resources to invest in the necessary clinical trials. To that end, we have been working diligently towards the transformation of the overall business to becoming a pure-play CDMO, while assessing the best strategic options for the R&D assets that would allow stockholders to directly see the future value from their continued developments. By partnering & eliminating future R&D expenditures, we believe we are best positioning Avid for future growth. Through reinvestment & expansion, we believe we will attract new customers and extend current contracts that will help position Avid as a leading U.S. CDMO. We are moving forward expeditiously with strategic discussions as we recognize the need to move quickly both from the R&D & CDMO standpoints. We hope to bring this process to completion over the coming months and will update you on our progress.”
7-14-17: Qtly. Conf. Call (King/Shan/Lytle) Transcript http://tinyurl.com/yb4wulvu
...CEO SK: “We are seriously considering the possibility of separating our 2 distinct businesses, Avid and R&D/PS-Targeting.”


EVERYTHING BELOW IS A HISTORY OF PEREGRINE PHARMACEUTICALS ANTI-PS PLATFORM, EARLY-2000'S THRU DEC. 2017:

Peregrine Pharmaceuticals, Inc. (PPHM), Tustin CA. http://www.peregrineinc.com is committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development & mfg. organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP mfg. & dev. capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com ), which provides development & biomfg. services for both Peregrine & 3rd-party customers. The company is also working to evaluate its lead immunotherapy candidate, BAVITUXIMAB, in combination with immune stimulating therapies for the treatment of various cancers, and developing its PROPRIETARY EXOSOME TECHNOLOGY for the detection & monitoring of cancer using assays that are able to detect small amts of PS+ Exosomes in a patient's blood sample. Bavituximab, a phosphatidylserine(PS)-targeting antibody, represents a new approach to treating cancer (3:34 video). Bavituximab was invented by UTSW's Dr. Philip Thorpe (1951-2013), and research continues in Dr. Rolf Brekken's UTSW lab.
BAVI MOA: By blocking the immunosuppressive signal of exposed PS, Bavi mediates multiple immunostimulatory changes in the tumor environment, including a reduction of tumor-promoting immune cells and an increase in tumor fighting (M1) macrophages, dendritic cells, and cytotoxic T-cells (CD8+ CD45+ CD3+) that fight solid tumors. (see: AACR'15 & ASCO'15 & ImVacS’15 & SITC'15 & S.King/1-18-16 & AACR'16 & AACR'17 & ASCO'17)
COLLABS: In addition to the ongoing UTSW/Brekken/Schroit research collab., Peregrine began working w/Mem-Sloan-Kettering(Jedd Wolchok Lab) in Jul'15(2 known studies a/o 4-2017: #1/Bavi+PD1+Rad, #2/Bavi+”ACT) to investigate “Novel PS-Targeting Immunotherapy Combos”, then w/AstraZeneca in Aug'15(see PR) to run human trials evaluating Bavi+Durvalumab(Imfinzi) in "mult-solid-tumor-types", and w/The Natl. Comprehensive Cancer Network (NCCN) in Jan'16 via a $2M res. grant to NCCN which will “significantly expand Peregrine's clinical evaluation of bavituximab” at “27 of the world's leading cancer centers” (9-16-16: NCCN selects 3 Bavi Trials to in 2017 at Moffitt/MassGen/JohnsHopkins). Also, w/Duke Univ. (See Dr. Herbert K. Lyerly: AACR-IO/10-22-16), MD Anderson (See Dr. Jason Fleming),  Rutgers Univ. (See Dr. Raymond Birge), and ImmunoVaccine Inc. (AACR'17 4-4-17 #3657). MORE on PreClin. Collabs: http://tinyurl.com/heg9t3v
AVID: Peregrine also operates Avid Bioservices, a wholly owned cGMP CMO subsidiary, which provides contract mfg. services on a fee-for-service basis (revs. May'06-Oct17=$271.1mm), as well as support of Peregrine's own product pipeline.
5-2017: Avid II(Myford) expands; total Avid mfg. capacity now > 11,000L - see http://tinyurl.com/ky7bmu4

4-2-13: Peregrine Mourns Loss of Dr. Philip E. Thorpe (1951-2013) http://tinyurl.com/l9gqmt5  
"Phil will be sorely missed as a colleague and friend. At Peregrine, each of us is pursuing Phil's dream of bringing important drugs to patients who need them based on his basic research. We are more motivated than ever to see this dream through."
…Dr. Thorpe’s successor at UTSW: long-time colleague, co-inventor of 2C3, Dr. Rolf A. Brekken, PhD - http://www.utsouthwestern.edu/labs/brekken

8-2014: UK colleagues from Chester Beatty Labs(ICR/Univ-London), ICRF(IsraelCancerRes), & UTSW create memorial for Dr.Thorpe in London’s Chelsea Physic Garden: http://tinyurl.com/lon73l7


SCIENCE: "Evolution has favored pathogenesis that resembles apoptosis."
Dr. Judah Folkman: ”This [Thorpe’s VTA research] is very promising and very elegant work... The whole goal is really 2-part, reducing the harsh side effects of cancer treatment, and reducing the chance that some cancer cells will evade treatment. That would be a big step in the next decade, and anti-vascular therapy will play a major role." (’97 & ’02 http://tinyurl.com/k5qe96g & http://tinyurl.com/n6vh9hp
Bavituximab MOA & Clinical Data: http://www.peregrineinc.com/pipeline/bavituximab-oncology.html
...Bavi Publications: http://www.peregrineinc.com/publications/publications.html
...Bavi Posters & Presentations: http://www.peregrineinc.com/publications/posters-and-presentations.html
Bavi MOA: Video (3:34) added ~3-2014 https://vimeo.com/87116642 "Bavituximab: A Novel Immunotherapy Candidate Targeting an Upstream Immune Checkpoint to Fight Cancer"
Bavi MOA: Video (1:33) on Bavi’s Immunotherapeutic MOA added to Youtube on 3-27-14 https://www.youtube.com/watch?v=Esewl35JD8s




Expert Quotes/Commentary On Bavituximab's Moa/Potential: http://tinyurl.com/nmdw4
Peregrine's Patent Estate - excl. licenses from UTSW MDA U-CALIF USC: http://tinyurl.com/58cn74
7-16-12 Form 10-K (fy/e 4-30-12): License Agreements between PPHM & UTSW/DNA/Avanir/Lonza (pg.10) http://tinyurl.com/agy6hn6
…Royalty %'s payable to UTSW/Dallas on sales of future-approved Anti-PS drugs will be in the "low single digits"
4-2006: Tarvacin (chimeric 3G4) will henceforth be referred to by its generic name, BAVITUXIMAB, to avoid confusion with OSI's anti-cancer drug Tarceva. http://tinyurl.com/2vawjv
10-1-17/JrnlRadONCO: “ChemoRad.+PSTargeting Enhances Anti-tumor Immune Responses (Mice)” (MDA+PPHM) https://tinyurl.com/yd7lrr8x
BAVI MOA 4-3-17 AACR'17: Joint Memorial Sloan Kettering (Wolchok Lab) & PPHM poster: “PS Targeting+Adoptive TCell Transfer (ACT) Eliminates Adv. Tumors w/o Off-Target Toxicities, Melanoma”  http://tinyurl.com/lxlltd6
BAVI MOA 1-30-17 Mol.Cancer article: MDA/J.Fleming, UTSW/Brekken, “PreClin. Eval of DNAtrix's DNX2401+BAVI for Pancreatic Cancer” http://tinyurl.com/hb6m3yj
...Combo DNAtrix's DNX-2401(Oncolytic Virus) + BAVI “significantly inhibited tumor growth; further enhanced its anticancer activity; warrants further clinical evaluation...”
BAVI MOA 11-14-16 SITC’16: Joint Memorial Sloan Kettering (Wolchok Lab) & PPHM poster on Triple Combo Rad+Bavi+aPD1 vs. Melanoma http://tinyurl.com/js3fca4
...Dr. Jedd Wolchok states, “Based on these study results, we believe that the targeting of PS is having meaningful activity within the tumor microenvironment in the B16 melanoma model. It appears that this activity creates a more immune active environment in which other treatments, including radiation, are able to have a greater anti-tumor impact." => AACR'17 Update 4-2-17 (#574) http://tinyurl.com/m7868sx

BAVI MOA 10-22-16: Duke’s Herbert K. Lyerly (w/PPHM) poster on AntiPS/TNBC data at AACR’s Tumor Immunotherapy Conf./Boston http://tinyurl.com/zzryfok
...”Modulating The Tumor Microenvironment to Enhance Cancer Immunotherapy by Inducing Phosphatidylserine Expression on the Tumor Surface”
BAVI MOA 9-27-16 AACR-CRI/Dr. Michael Gray: Preclin. Triple-Combo Bavi+PD1+LAG3 TNBC data in TNBC (80% Compl. Regression, Stat-Sig. Incr. in Key Tumor Fighting Immune Cells) http://tinyurl.com/zy9yv78
BAVI MOA 7-27-16 Shaul/Brekken/Thorpe/etal PLOS ONE article: Fhu/Bavi vs. APS-related Pregnancy Complications & Thrombosis http://tinyurl.com/jlhrdg2
...”The potential clinical impact of 1N11 (Fhu Bavi) in patients with APS is substantial. Spring-boarding from the present discovery of 1N11 as a highly-effective, mechanism-based treatment for APS in a comprehensive series of mouse models of APS-related disorders, clinical studies of 1N11 now warrant consideration.”
BAVI MOA 5-11-16 Breast Cancer Res. article, B.Freimark/M.Gray/CW.Hughes-et-al, “PS-Targeting/Bavi Combo w/Anti-PD1/PDL1 in Triple.Neg-MBC” http://tinyurl.com/zxu882y
...”our observations demonstrate that including PS-targeting antibodies such as bavituximab can enhance the anti-tumor activity of anti-PD-1/PD-L1 treatments, not only by increasing TIL responses but also by inhibiting cytokines stimulated by single-agent anti-PD-1 therapy that serve to suppress the immune response & promote tumor progression.”
BAVI MOA 4-20-16/AACR'16 & 4-4-16/Cancer-Immunology-Res.(AACR) article - preclin. data: Bavi combo w/anti-PD-1/anti-CTLA-4 “induces a shift in tumor microenvironment from immunosuppressive to immune active” http://tinyurl.com/jyox458
BAVI MOA 1-18-16: CEO Steve King explains PPHM's direct PS-Targeting advantage vs. the “individual-receptors” PS-binding approach of others like: Axl Mer TIM-3 RAGE Tyro3 GAS6 CD300a BAI1 MFG-E8 etc. http://tinyurl.com/h2h87mc
2-2016: Rutgers' Dr. Raymond Birge's relationship with Peregrine & UTSW's Dr. Rolf Brekken and his 2-26-16 article, “Phosphatidylserine is a Global Immunosuppressive Signal in Efferocytosis, Infectious Disease, and Cancer”  http://tinyurl.com/z5d9qt9 and 9-26-16 AACR/CRI, “Characterization of a PS, TAM Receptor (Tyro3, Axl, Mertk), PDL1 Axis in Breast Cancer” http://tinyurl.com/ldlzka8

11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (DUKE's Herbert K. Lyerly + PPHM + UTSW) http://tinyurl.com/pbof95w
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca) - ”Combining Bavi w/anti-PD-1 significantly enhanced O/S… significant incr. CD45+, CD8+ and CD3+ T-cells… led a prolonged anti-tumor immune response which protected the animals against a re-challenge w/same tumor.”
BAVI MOA 8-26-15: Jeff Hutchins(VP/PreClin-Res) ImVacS’15 Talk – 29pg. Slideshow http://tinyurl.com/qz64pzg
…“Expansion & Activation of T Cells via the Targeting of the Immunosuppressive Ligand PS: Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy”
5-31-15: ASCO’15 Roundtable (webcast), “Raising the Immuno-Oncology Bar” - 7 panel members, incl. 3 Sloan Kettering researchers http://tinyurl.com/qxu4w2x
BAVI MOA 3-25-15: PPHM/VP Dr. Jeff Hutchins’ presentation at "Immune Checkpoint Inhibitors Conf.", Boston - PDF(34 Slides): http://tinyurl.com/ooxkhq7
BAVI MOA 2-9-15: PPHM's Dr. Bruce Freimark’s presentation at KEYSTONE "Tumor Immunology Meeting", Banff/CN – PR & Slides: http://tinyurl.com/q6cx4w6
2010-2014 ARCHIVE OF ANTI-PS/BAVITUXIMAB MOA ARTICLES/PRESENTATIONS: http://tinyurl.com/y93r4jva
- - - -Peregrine's Anti-PS Mabs:
• PGN635 (B2GPI-dep.) is Fully-Human Bavituximab=1N11=AT004 (B2GPI-depen.); Genentech studying 89Zr-PGN635 as a Tumor Imaging Agent, “indep. of cancer type”
• PGN632 (B2GPI-indep.) is the Duke-PPHM-HIV candidate=11.31=AT005; also being studied by PPHM+LSU vs. Ocular Herpes (Acute HSV-1 Keratitis), see http://tinyurl.com/cax9a4p
• PGN650 is a human F(ab’)2 fragment that targets PS expression (1st ref’d in AACR’12 #2452) – see http://tinyurl.com/76nqqkm . 124I-PGN650 is Peregrine’s PS-Imaging candidate (see http://tinyurl.com/7p7jovt )
BETABODIES (Clipped/Nicked B2GPI - ex: KL15, “2nd-gen. PS-Targeting”) - bind to PS directly, are smaller in size (100 vs. 250KDa) and have a longer serum half-life (~5days) than natural antibodies (Bavi=~1day) – see http://tinyurl.com/khopa3d
...6-22-17: Nature(BJC): AntiPS Exosomes in Breast & Pancreatic, Alan Schroit/Rolf Brekken etal (UTSW/PPHM SAB) - Betabody KL15C being tested. http://tinyurl.com/ycrx9672
…2/17/15: UTSW/PPHM’s BetaBodies patent#8,956,616 Awarded(Granted) http://tinyurl.com/p75uyfu


Examples of anti-PD-1 drugs in development: (PD1=”Programmed Cell Death Protein 1”)
1. Merck’s Keytruda(pembrolizumab=MK-3475, formerly=labrolizumab) <=’14/Melanoma, ‘15/NSCLC, ‘16/Head&Neck
2. BMS’s Opdivo(nivolumab) <=’14/Melanoma, ’15/NSCLC & RenalCell
3. AZN/MedImmune’s MEDI0680 (formerly=AMP514)
4. GSK’s AMP-224 (collab. with Amplimmune)
Examples of anti-PD-L1 drugs in development: (PD-L1=”PD1 ligand”)
1. BMS’s BMS-936559 (MDX-1105)
2.. Roche/DNA’s Tecentriq(atezolizumab, aka MPDL3280A) <=2016/Bladder & 2L/NSCLC
3. AZN/MedImmune’s Imfinzi(durvalumab=MEDI4736)<=2015 PPHM+AZN collab. & expansion to run trials in Lung & "mult. tumor types"
4. Pfizer/Merck-KgaA’s Avelumab (formerly MSB0010718C)
7-14-14/CC: Steve Worsley (VP/BusDev) said that Peregrine is “seeking collaborators that build on other checkpoints of pathways such as PD-1, IDO, immune-stimulatory drugs, and even vaccines…”  http://tinyurl.com/zor2vjs
...Interesting: PPHM KOL/SRB’r Dr. Scott Antonia’s (Moffitt-CC/Tampa) role in IDO dev: http://tinyurl.com/mol86st <=“1st to report in 2002 that IDO inhibitors delay growth of human lung cancer cells”
Incyte’s immune checkpoint inhibitor INCB24360 is an oral inhibitor of IDO1 (indoleamine dioxygenase-1) – http://www.incyte.com
NewLink Genetics’ immune checkpoint inhibitor indoximod is an oral inhibitor of IDO (indoleamine 2,3-dioxygenase) – http://newlinkgenetics.com
...“IDO pathway inhibitors are another class of immune check point inhibitors akin to the recently developed antibodies targeting CTLA-4 & PD-1 that represent potential breakthrough approaches to cancer therapy.”


EMPLOYEES:
"As of 4-30-17, Peregrine employed 319 full-time emps & 4 part-time emps." ('11=154/2, '12=172/2 '13=182/4 '14=180/4 '15=211/4 '16=281/3) http://tinyurl.com/yb4wulvu
8-9-17: PPHM commenced a restructuring plan… expected to be completed in Oct’17… reduced workforce by 60 emps (20%), reduced R&D from 22 to 11. http://tinyurl.com/ycrxq5tc
...On 3-18-09, CFO P.Lytle (Cowen/Boston) stated, "We have 135 emps, 85 under Avid Bioservices, and the remaining 50 emps reside at the Peregrine corp. level - 35 in R&D & 15 in G&A."
In 10-2009, Dr. Robert Garnick joined Peregrine as Head/Regulatory ( http://tinyurl.com/yga7z4x ).  In his 24 years at Genentech (1984-2008; from Feb'01-Oct'08 as Senior V.P. of Regulatory, Quality & Compliance), he was responsible for 17 new product approvals, including most of DNA's top selling monoclonal antibody therapeutics such as Rituxan, Herceptin, Avastin, and Lucentis.  He was responsible for all the regulated aspects of Genentech's business, including drug development, commercial production, and promotional & labeling compliance.  As CEO Steve King said 6-29-11, "Rob is the ringmaster."
• See this 6-29-11 Minyanville article, "Peregrine Pharma's Secret Weapon"  http://tinyurl.com/9jtnano
• Examples of Dr. Garnick's work at Genentech on Avastin (bevacizumab) approvals: http://tinyurl.com/yg7vtqa  
• All of Dr. Robert Garnick's public comments (thru 3-7-2014) while at Peregrine: http://tinyurl.com/obvwyuh

ANALYST COVERAGE:
8-6-10: Bavituximab listed #8 in EP-Vantage's 'Biggest Unpartnered Pipeline Assets' chart, with NPV=$1.022b: http://tinyurl.com/34lpt5j
5-22-13: Citigroup analyst Andrew S. Baum’s report, "Immunotherapy - The Beginning of the End for Cancer" http://tinyurl.com/pob7ktc
…”A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history… We believe this market will gen. sales of up to $35B/yr. over the next 10yrs and be used in some way in the mgt. of up to 60% of all cancers…”
Noble Life Science Partners/Caroline Palomeque https://noblecapitalmarkets.com/life-science (init. 7-16-15); 12-12-17: Buy/PT=$10.00
FBR & Co./ThomasYip http://brileyfbr.com/ 9-9-16: Outperform/PT=$1.00
Roth Capital /Joe Pantginis (init. 7-15-10), 7-15-16: Neutral/$.50 http://www.roth.com <="In Transition" a/o 12-2016
MLV/George B. Zavoico(Jones Trading?) - init. 2-8-10 Buy/PT=$10, CURR: Buy/$3.50 http://www.mlvco.com <=dropped 2015
Piper Jaffray/Charles Duncan - init. 3-5-13 <=Coverage dropped 12-2015
JMP Securities/Jason Butler - init. 8-30-2011 OutPerf/PT=$5, CURR: OutPerf/$6.50 http://www.jmpg.com <=7-2014: dropped from PeregrineInc.com
LifeTech-Cap/Steve Dunn - init. 4-14-10 Spec-Buy/PT=$8, CURR: Spec-Buy/$5 <=Dropped 4-2012
1-2011: PPHM has Exec. Info. Report (EIO) prepared by Crystal Research (Jeffery Kraws): http://tinyurl.com/2dja6uo
12-21-07/Terminated: Rodman&Ren. (Jaikaria/Benjamin) initiate: Mkt-Perform: http://tinyurl.com/624dmd


PPHM's EXOSOME-BASED (PS Positive) CANCER DETECTION & MONITORING TECHNOLOGY ("Liquid Biopsy")
...Excellent Exosome (aka microparticles, microvesicles) info: http://www.exosome-rna.com
9-11-17/Status: "The company continues to make progress... The assay has been successfully optimized; we are evaluating options to license/partner/sell this technology." http://tinyurl.com/y9y8qdac
6-22-17: Nature/BJoC, Dr. Alan Schroit/UTSW etal: "Detection of PS+ Exosomes for the Diagnosis of Early-Stage Breast & Pancreatic [Betabody KL15C]" http://tinyurl.com/yd3n5kbk

2-9-17/PR: PS+ Exosomes Proof-of-Concept Data (N=44, Ovarian, Dr. Alan Schroit/UTSW etal) pub. 1-22-17 in OncoTarget http://tinyurl.com/jhv57ua
...Data (blinded plasma from 34 O.C. pts & 10 healthy subjects) supports the “high diagnostic power” of PS+ Exosomes in Ovarian Malignancies.
...Dr. Stephen Worsley (VP/BusDev): “...we believe this has potential app's in several solid tumors beyond ovarian cancer. With that in mind, we look forward to aligning with a partner to help explore the potential of this promising technology."
...PPHM’s PS Exosomes platform advantages outlined: UTSW/website and World Patent #WO/2016/201064: http://tinyurl.com/zbwr7cc
......U.S. Patent app. #20170146542 “DIAGNOSTIC TEST FOR EARLY STAGE CANCER” pub. 5-25-17 (A.Schroit, S.Ward, A.Gazdar) http://tinyurl.com/y7clom9w
7-14-16: Peregrine Licenses Exosome-based technology from UTSW (Inventors: Alan Schroit/Philip Thorpe) http://tinyurl.com/zszd4fj
...“relates to assays that are able to detect small amts of PS+ Exosomes in a patient's blood sample as a way to detect cancer at a very early stage of development.”
...Dr. Jeff Hutchins (VP/PreclinRES): "Once we have successfully validated this assay, we plan to establish proof-of-concept through an efficient preclinical & clinical testing pgm. We have no intention of conducting further development work beyond the proof-of-concept stage. Rather, we expect to initiate partnering discussions for commercialization of this pgm in 2017.
"

3 NCCN Bavituximab Trials Announced 9-6-16 ($2mm grant from PPHM) http://tinyurl.com/gutgwb5
#1: Ph1/HepC-Related Hepatocellular(Liver) (Bavi+RAD+Bayer’s Nexavar=Sorafenib), MOFFITT CC (N=18)
. . . . . . .PI: Jessica Frakes, MD https://clinicaltrials.gov/ct2/show/NCT02989870 <=Recruiting a/o 3-27-17
#2: Ph2/Newly Diag. Glioblastoma (Bavi+RAD+Merck’s Temodar), MASS-GEN. & DANA FARBER (N=36)
. . . . . . .PI: Elizabeth Gerstner, MD https://clinicaltrials.gov/ct2/show/NCT03139916 <=Recruiting/6-16-17; 1stDose/9-7-17
#3: Ph2/Progressive Squamous Head+Neck (Bavi+Merck’s Keytruda), JOHNS-HOPKINS(Sidney Kimmel CC)
. . . . . . .PI: Ranee Mehra, MD https://clinicaltrials.gov/ct2/show/XXXXXXXXX - See Dr. R.Mehra Jan'17/IFN-y Biomarker: http://tinyurl.com/h8gzkww

BAVITUXIMAB "SUNRISE" PHASE III TRIAL: (Start=Dec'13 EstPrimComp=Dec’16)
A. Phase III Bavi+Doce vs. 2nd-Line NSCLC "SUNRISE" (randomized, double-blind, placebo-ctl'd, n=582)
USA Protocol: http://www.clinicaltrials.gov/ct2/show/NCT01999673 <=chgd. to "Active, Not Recruiting." 2-1-16
...2 ARMS: A=BAVI/3mg+DOCE(Weekly), B=Doce+Placebo(Weekly)
...ECOG's: Ph3SUNRISE/0-1, Ph2Bavi+Doce(n=120)/0-1-2, Ph2Bavi+Durva(AZN)/0-1, Ph3Herbst2010/0-1 (2L/NSCLC)
...161 sites a/o 7-9-15 (USA/39 Aus/9 Bel/7 Fr/9 Ger/15 Greece/10 Hungary/7 Italy/10 Korea/9 Rom/6 Rus/8 Spain/16 Taiwan/10 Ukraine/6) - Growth: http://tinyurl.com/qbemrr2
...Sunrise Biomarker studies - 4 announced thru ASCO'17, see http://tinyurl.com/ydhf6tfx
......#1 10-10-16/ESMO’16: B2GPI/200-240(30%pts) StatSig MOS 7.7=>13.2mos. http://tinyurl.com/hp73njt
......#2 12-7-16/WCLC’16(IASLC): “Complement & IL-10 Pathways: Pts Benefiting from Bavi+Doce” <=Presentation CANCELLED/”Anal.Not.Finished(IR)” http://tinyurl.com/z8cq8vx
......#3 4-3-17/AACR'17: "IFN-y Analysis In Blood & Tissue as a Potential Prognostic and/or Predictive Biomarker” See: http://tinyurl.com/ktzr782
......#4 6-3-17/ASCO'17: "Prelim. Correlative Analysis of PD-L1 Expression from the Sunrise Study” See ASCO'17: http://tinyurl.com/y93upatl
10-17-17/WCLC’17(IASLC): SUNRISE Subset Data (n=93) http://tinyurl.com/ydcrc4xb ”N=46 rec. ICI after Bavi/MOS not yet reached v. n=47 didn’t rec. Bavi/MOS=12.6mos.”
9-9-17/ESMO’17(Madrid): Final SUNRISE Ph3 Data to be presented (poster# 1364P) http://tinyurl.com/yb9kjutp
..."In an exploratory analysis of OS for pts who received subsequent immune checkpoint inhibitors (ICI), mOS was not reached.”
2-25-16: IDMC Halts SUNRISE at 1st Look-in. Bavi+Doce arm “OS performing as expected”; Doce arm “dramatically outperforming OS expectations” http://tinyurl.com/jbg48vs
...CC Replay: http://edge.media-server.com/m/p/xfa9fy5v 12:22/Q&A: RahulJasuja/Noble, “You said that the performance of the Doce/Ctl arm was higher than ever seen in such a trial?” - SK “Yes, we've never seen these #'s reported. It's quite perplexing… at this point, the performance of the Doce arm was just completely out in left field.”
2-1-16: SUNRISE Trial status updated: “Study ongoing, but not recruiting.” http://www.clinicaltrials.gov/ct2/show/NCT01999673
12-10-15: “Sunrise >90% enrolled; sufficient to allow the 2 planned interim looks (33%/50%) & final readout based on PrimEndPt=OS” http://tinyurl.com/jkp885g
5-31-14 ASCO’14: David Gerber/Joe Shan Poster on Ph3/SUNRISE Trial (#TPS8129) http://tinyurl.com/nv4jloo
3-7-14: PR & Conf-Call: "first patients enrolled and dosed." http://tinyurl.com/kh9cnrg
1-6-14: FDA grants FAST TRACK status to Bavi in 2ndLine NSCLC http://tinyurl.com/l799ukk
12-30-13: Pivotal Ph.3 ‘SUNRISE’ NSCLC Trial Initiated (n=~600, sites=100+) http://tinyurl.com/kdjb9qz
5-20-13: FDA Approves Bavituximab Ph.III Design for 2L/NSCLC; 600-pt trial to begin by y/e’13 http://tinyurl.com/n3dxtm6
...S.King: “We will now focus on starting the Ph.III trial while continuing ongoing partnering discussions.”
…R.Garnick: “This was a highly collaborative effort with the FDA; this trial, when combined with Bavi’s supporting data to date, could be sufficient to support a future BLA submission."


15 COMPLETED PH. I/II BAVITUXIMAB CANCER TRIALS (2005-2015):
These 2nd 10 (latest ones, 2010-2015) completed Ph.1/2 Bavi Trials archived to: http://tinyurl.com/ybjap4fb
O. 6th IST Trial: Bavi+Ipilimumab(Yervoy) vs. Adv.Melanoma (Ph1b, random, open-lab, 2arms, n=24)
N. 5th IST Trial (Bavi+Capecitabine+RAD) vs. Rectal Cancer (Ph1, open-lab, 1arm, n=18)
M. Tumor Imaging/Dosimetry trial of I124-PGN650 (FH-Bavi) in Adv. Solid Tumors (Ph0, open-lab, 1arm, n=12)
L. 4th IST Trial (Bavi+Cabazitaxel vs. PROSTATE, open-lab Ph.1B/IIA) CANCELLED/SOC-Chg.
K. 3rd IST Trial (Bavi+PemCarbo vs. Frontline NSCLC, open-lab Ph.1B, n=25)
J. 2nd IST Trial (Bavi+Paclitaxel(Taxol) vs. Her2- Met. Breast Cancer, open-lab Ph.1, n=14)
I. Ph.II Bavi+GEM vs. Front-Line Adv. PANCREATIC (randomized, unblinded, n=70)
H. 1st IST Ph.I/II Trial (Bavi+Sorafenib vs. Liver, open-lab, n=9+38=47)
G. Ph.IIb Bavi+PC vs. Front-Line NSCLC (randomized, unblinded, 'confirmatory', n=86)
F. LEAD IND: Phase IIb Bavi+Doce vs. 2nd-Line NSCLC (random/double-blind, n=120, 'registrational')
These 1st 5 (oldest ones, 2005-2009) completed Ph.1/2 Bavi Trials archived to: http://tinyurl.com/72dnkfg
1. Ph.1A Bavi/Mono vs. Solid Cancers (USA n=26, 6/2005-6/2009)
2. Ph.1B Bavi+Chemo vs. Solid Cancers (India n=12, 11/2006-5/2007)
3. Ph.2 Bavi+Doce/BREAST/Refractory (RepGA n=46, 1/2008-5/2009): ORR=61%(Her2+=86%), MOS=20.7mos
4. Ph.2 Bavi+PC/BREAST/Frontline (India n=46, 8/2008-9/2009): ORR=74%(Her2+=100%), MOS=23.2mos
5. Ph.2 Bavi+PC/NSCLC/Frontline (India n=49, 6/2008-10/2009): ORR=43%, PFS=6.1mos, MOS=12.4mos


COMPANY UPDATES & ARTICLES: [ PPHM News: http://finance.yahoo.com/q/h?s=PPHM ]
1-18-18: Peregrine's 2017 ASM (Avid/Myford, Tustin) ...PROXY/14A iss. 12-7-17: https://tinyurl.com/y7qprpg9
12-26-17: Roger Lias replaces Steven King as Pres./CEO; in process of changing name to Avid Bio. and new Nasdaq Ticker ("early 2018") https://tinyurl.com/yb34e2t8
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6

...Dr. Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
11-28-17: PPHM+RONIN Settle - Reconstituted 7-Member BOD (Johnson/Swartz/Pohl/King resign) https://tinyurl.com/y7g72zh4
...Full Agreement(8-K): Header: https://tinyurl.com/y8m35nax Complete Agreement: https://tinyurl.com/y7b3gkc2
...Profiles of all 7 BOD members & Compensation as of 11-28-17: https://tinyurl.com/y9lkl4q2
.....(Joseph Carleone/Chair, Richard Hancock, Gregory Sargen, Joel McComb, Roger Lias, Mark Bamforth, Patrick Walsh)

Sept-Nov2017 PPHM/Form4’s for reconstituted 7-person BOD (Options Awarded):
...Joseph Carleone (Chairman): 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Richard Hancock: 75,000 @4.67 vesting monthly over 3yrs beg. 12-27-17
...Gregory Sargen: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Joel McComb: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Patrick Walsh: 75,000 @4.08, vesting monthly over 3yrs beg. 11-20-17
...Mark Bamforth: 75,000 @3.88, vesting monthly over 3yrs beg. 11-17-17
...Roger Lias: 150,000 @3.19, vesting in 4 equal annual installments beg. 9-25-18
...OPEN MKT PUR: Mark Bamforth Buys 50,000sh. @$4.50 (open mkt) on 10-27-17 http://tinyurl.com/ya7pyyu5

11-15-17/Outsourcing-Pharma: “How This R&D Company (Peregrine) is Transitioning to a Pure-Play CDMO: ‘Opportunities Are Almost Endless’" - Recap of interviews with Steve King & Avid Pres. Roger Lias http://tinyurl.com/y7dv9faz
11-13-17/PR: Peregrine's 2017 ASM to be held 1/18/18 at Avid (VotingRecDate=11-27-17): http://tinyurl.com/y8b2rjkg
10-23-17/8-K: “Recently Amended” BOD Compensation Pgm http://tinyurl.com/y7mvg6wt  $55000/yr + $15000/committee + $2000/meeting
10-24-17: Peregrine Adds Patrick D. Walsh to BOD, "An Industry Veteran with 30+yrs Experience Leading Successful CDMO Org’s” http://tinyurl.com/ydxlv7sb
10-19-17: Peregrine Adds Mark R. Bamforth to BOD, "10yrs/Genzyme; 30yrs of biologics leadership experience, incl. founding 2 CDMOs" http://tinyurl.com/ydxlv7sb
...10-27-17/Form4: Mark Bamforth buys 50,000sh. @$4.50 (open mkt): http://tinyurl.com/ya7pyyu5
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s President and join PPHM’s BOD eff. 9-25-17 http://tinyurl.com/yd3eh3uv
9-11-17: Qtly. Conf. Call (King/Lias/Lytle) Transcript http://tinyurl.com/y9y8qdac
...CEO SK: “For this reason, we have concluded that in order to best position Peregrine’s R&D assets for successful development, they should be advanced by a partner with the appropriate expertise and ample resources to invest in the necessary clinical trials. To that end, we have been working diligently towards the transformation of the overall business to becoming a pure-play CDMO, while assessing the best strategic options for the R&D assets that would allow stockholders to directly see the future value from their continued developments. By partnering & eliminating future R&D expenditures, we believe we are best positioning Avid for future growth. Through reinvestment & expansion, we believe we will attract new customers and extend current contracts that will help position Avid as a leading U.S. CDMO. We are moving forward expeditiously with strategic discussions as we recognize the need to move quickly both from the R&D & CDMO standpoints. We hope to bring this process to completion over the coming months and will update you on our progress.”
7-14-17: Qtly. Conf. Call (King/Shan/Lytle) Transcript http://tinyurl.com/yb4wulvu
...CEO SK: “We are seriously considering the possibility of separating our 2 distinct businesses, Avid and R&D/PS-Targeting.”
3-13-17: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/grhwjvy
...CEO SK: “We believe the recent improvement of stock price is a growing recognition of the value of Avid, and having the full value of the Avid business reflected in our stock price is a top priority.”
12-12-16: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/hhn4gga
...CEO SK: “Our goal is to bring the overall company to profitability within the next 18mos. We believe just the value of Avid Bioservices is far greater than our current market cap and is only growing in value."
10-13-16 Peregrine's ASM: ATTENDEE Reports & Link to CEO Steve King's 35min/45slide webcast: http://tinyurl.com/jx7ouay
9-8-16: Qtly. Conf. Call (King/Shan/Garnick/Hutchins/Lytle) Transcript http://tinyurl.com/jydtkoy
...CEO SK: “Our ultimate goal remains to reach overall profitability within the next 21mos, and Avid will be an important driver for achieving that goal, in combination with making strategic investments in our R&D while pursuing partnerships to help advance our programs.”
7-14-16: Qtly. Conf. Call (King/Garnick/Hutchins/Shan/Lytle) Transcript http://tinyurl.com/h8eqtg5 (Avid revs guidance for FY17=$50-55mm, curr. committed B/L=$68mm)
...CEO SK: “The recent licensing of Novel PS Exosome Tech. for detection/monitoring of cancer from UTSW will allow the co. to continue its R&D activities with significant upside coming from partnering as we move towards profitability.”
6-2-16: Corp.Update – Avid Expansion & Drug Development - http://tinyurl.com/zvmhqmr
...Avid Revs for FY16(fye 4-30-16) will be $44mm; B/L=$56M; FY17/guidance=$50-55mm(3 curr. clients). Avid III being designed/already secured 25,000sf loc/expect complete=1H/2017. “Expect future sustainable profitability for the company in 24mos.”
3-9-16: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/gom7md5
...CEO SK: “Peregrine remains a strong company with a valuable clinical asset and a rapidly growing biomfg. business... We believe our relationships with AstraZeneca, Mem. Sloan Kettering, UTSW, & NCCN will be invaluable as we establish & execute our overall strategy for advancing the bavituximab I-O combination plans in a range of cancers.”
3-7-16: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs) http://tinyurl.com/za2j9mt
2-25-16: IDMC Halts Ph.3/NSCLC SUNRISE Trial at 1st Look-in. Bavi+Doce arm “OS performing as expected”; Doce arm “dramatically outperforming OS expectations” http://tinyurl.com/jbg48vs
1-18-16: CEO Steve King's 1-18-16 presentation at Noble-Financial's Investor Conf. (21min replay, 31 slides) http://tinyurl.com/j9dkekm
1-11-16: Update on 4 New Bavi Clinical Trials (Lung/AZN, Breast/1Co./1MSKCC, Other Cancers/AZN). SUNRISE est's: Look1=Early'16, Look2=Mid'16, FinalUnblind=End'16 http://tinyurl.com/zhdy37a
1-6-16: Peregrine enters into Research Collab. with Natl-Comprehensive-Cancer-Network (NCCN) http://tinyurl.com/zmxtpsb
...$2mm res. grant to NCCN's Oncology Res. Pgm (ORP), will “significantly expand our clinical evaluation of Bavi and augment Peregrine's IST pgm at 26 of the world's leading cancer centers”.
12-10-15 Qtly. Conf. Call (King/Shan/Worsley/Garnick/Lytle) Transcript http://tinyurl.com/jkp885g
...CEO SK: “Although our SUNRISE enrollment milestone has been reached, we have no intention of slowing down, quite the opposite. We are aggressively moving to initiate new clinical trials [Lung, Breast, Mult-Types] that will allow us to build the most robust oncology business possible… With each of these studies our goal is the same - we are committed to identifying key indications, patient populations, and therapeutics that can benefit from combination treatment with bavituximab. From what we have seen to-date, the opportunity appears vast and we are hard at work converting the most promising prospects into true value.”
10-15-15 Peregrine's ASM: ATTENDEE Reports & Link to SK's 18min/16slide webcast: http://tinyurl.com/o6z4bm4
10-15-15: Peregrine & AstraZeneca Expand Collab. w/Ph2/2ndLine-NSCLC Trial, Bavi+Imfinzi(durvalumab), squamous or non-squamous. http://tinyurl.com/q79bkam
9-9-15: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/ph22vdn
...CEO S.King: “The Memorial Sloan Kettering & AstraZeneca collaborations are an important part of our announced plans to expand our bavituximab clinical pgm.”
8-24-15: AstraZeneca & Peregrine Collaborate on Bavi+Imfinzi(durvalumab) Ph1/1B Trial for “multiple solid tumors” http://tinyurl.com/owlxpsf
...Imfinzi=durvalumab=MEDI4736(anti-PD-L1 immune checkpoint inhibitor). AZN’s Head/I-O(Robert Iannone): “Our partnership with Peregrine provides the opportunity to explore an exciting, novel combination that could deliver important clinical benefit to patients across a range of cancers."
7-14-15: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/nw2v5u6
...CEO S.King: “We recently entered into collaboration with investigators at Memorial Sloan Kettering Cancer Ctr to continue expanding on this important work, as well as to explore other potential applications of bavituximab and other agents that target PS-signaling pathway.”
5-29-15: Peregrine & Sloan Kettering Enter Collab. to “Investigate Novel PS-Targeting Immunotherapy Combos” http://tinyurl.com/o3k9ux8
3-12-15: Qtly. Conf. Call (King/Garnick/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/q78oxvm   
...CEO S.King: “Bavituximab represents the most clinically advanced agents that target the immunosuppressive PS signaling pathway, and we are driven to bring this product to the market and believe it has the potential to help change the way cancer patients are treated. Our Ph.3 SUNRISE NSCLC trial continues to make great progress & is on track to complete enrollment in the study by YrEnd’15.”
3-9-15: CEO Steve King’s 24min. talk at ROTH Conf. (DanaPT CA) - SLIDES http://tinyurl.com/p873grw 
12-10-14: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/kmdgq8t
...CEO S.King: “We believe Peregrine is in a unique position with an immune-oncology program already in Phase III, with what has been a positive safety profile and a target that is ideal for combining with other IO agents.”
10-16-14 Peregrine's ASM: Slides(42), Audio-Replay-Link, Attendee-Reports http://tinyurl.com/oyc3e5v
9-9-14: Qtly. Conf. Call (King/Hutchins/Shan/Lytle) Transcript http://tinyurl.com/ktrfswj
...CEO S.King: “In addition to our clinical trials, many of which have also have translational data points built in to tie together pre-clin. data with the clinic, we have also continued to build momentum in our pre-clin. collaborations which now number in the dozens. We are evaluating new combinations & dosing strategies combining bavituximab with chemotherapy, radiation, and immune-oncology approaches, including those targeting CTLA-4, PD-1, as well as other downstream immune checkpoints."
7-14-14: Qtly. Conf. Call (King/Shan/Hutchins/Worsley/Lytle) Transcript http://tinyurl.com/o2e4a4g
...CEO S.King: “Partnering remains a priority with the goal being to use partnerships to continue expanding the bavituximab program, while we continue to execute the SUNRISE Phase III trial.” 
3-10-14: CEO Steve King’s 22min. talk at ROTH Conf. (DanaPT CA) - SLIDES http://tinyurl.com/n65myfk
3-7-14: Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript http://tinyurl.com/kh9cnrg
...CEO S.King: “I don't want to overuse the word ‘excitement’, but these are truly exciting times that have positioned us for success on all fronts.” 
12-10-13: Qtly. Conf. Call (King/Shan/Garnick/Hutchins/Worsley/Lytle) Transcript http://tinyurl.com/mw776mk
...With recent scientific insights highlighting bavi’s immunostimulatory moa, these additions to PPHM’s SAB: Dimitry Gabrilovich, Scott Antonia, David Carbone, Hakan Mellstedt
...CEO S.King: “We believe that Peregrine is uniquely positioned among the companies developing immunotherapies… and that because of our current valuation, we represent a unique investment opportunity.” 
11-2013: Stephen Worsley joins Peregrine as VP of Bus.Dev. http://tinyurl.com/mmet4eb 
11-12-13: CEO Steve King's 23min. talk at Credit-Suisse Conf. (Scottsdale) http://tinyurl.com/nu3vxgt 
9-9-13 Qtly. Conf. Call (King/Hutchins/Shan/Lytle) Transcript http://tinyurl.com/q3zooj6
...CEO S.King: “In addition to the immunotherapy research, there has been significant interest in the results presented at ASCO showing an 84% tumor response rate in HER2- breast cancer patients.”
8-14-13: CEO Steve King's 26min. talk at Wedbush/NYC http://tinyurl.com/m22n9pl - SK. "We have very active partnering discussions [ongoing] around our 2 lead programs.”
7-11-13: Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript http://tinyurl.com/khpokw6
...CEO S.King: “This [new bavi] moa insight has opened the door to completely new combinations not previously explored.  Bavi acts on an upstream immune checkpoint, and thus, makes a potentially ideal combination with downstream-acting immune checkpoint inhibitors such as anti PD1 antibodies & CTLA-4 targeted approaches…  Preclinical studies are well underway to explore these combinations, and we look forward to generating and reporting data later this year that could support moving these concepts into the clinic.”
6-27-13: Updates on Bavituximab Pgm. & Cash Position http://tinyurl.com/pmcgsgp
…“primary focus remains on the init. of the PhIII trial in 2nd-Line NSCLC by y/e; recent data supporting an immunotherapy moa for bavituximab opens many new development opportunities including new combinations not previously planned and has created a lot of excitement around the potential of bavituximab in combination with other immunotherapeutic agents…"
4-2-13: Peregrine Mourns Loss of Dr. Philip E. Thorpe (1951-2013) http://tinyurl.com/c5zhd4q  
3-18-13: CEO Steve King's 27min. talk at Roth Conf.(DanaPT CA) - Excerpts & SLIDES http://tinyurl.com/cebtwen  
…CEO S.King: "Our goal is to initiate the Phase III trial (2ndLine NSCLC) by the end of 2013."
3-12-13: Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript http://tinyurl.com/c48osut   
...Rob Garnick (Head/Reg.): "Re: 2nd-Line NSCLC: …the 3rd piece, which is important, is the efficacy piece, and as I point out to many people, there are very few and far between Phase II trials that ever show statistical significance in efficacy - that's an absolutely unbelievable hurdle for a Phase II product.  And, what you're really looking for is an ability to describe that you do have clinical efficacy, and as Joe has said, showing 11.7 mos. for the 3mg arm and a difference in the pooled dataset for the product of 7.3 mos. when you combine the control & the placebo, definitely gives you the indication that in overall survival, we have a potentially highly efficacious product… we're going to discuss the entire situation of the investigation with the agency, as well as all the data I just described, and we feel pretty confident that we have enough data to move the product effectively into Phase III."
3-5-13: CEO Steve King's 24min. talk at Cowen HC Conf.(Boston) - Excepts & SLIDES http://tinyurl.com/bczyfb3

ARTICLES, ANNUAL SHM'S, & CC'S - Archive 2010-2012: http://tinyurl.com/y9t456ku
ARTICLES, ANNUAL SHM'S, & CC'S - Archive 2005-2009: http://tinyurl.com/6pjqt27

BAVITUXIMAB ANTI-CANCER NEWS (see above for Trials Info):
4-4-17: AACR'17: 5 posters, incl. new 2nd MSKCC/Wolchok Bavi+ACT study - http://tinyurl.com/m7868sx
4-20-16 AACR'16 & 4-4-16/Cancer-Immunology-Res.(AACR) article - preclin. data: Bavi combo w/anti-PD-1/anti-CTLA-4 “induces a shift in tumor microenvironment from immunosuppressive to immune active” http://tinyurl.com/jyox458
6-1-15 ASCO’15: 3 Bavi/AntiPS Posters (NSCLC, Melanoma, Breast, Liver) & Plans to add Ph2/3 Bavi Trials (NSCLC/Optivo, Her2- Breast) http://tinyurl.com/qxu4w2x
4-20-15 AACR’15: 3 Abstracts/2 PR’s - Bavi Clinical TransData/Lung & PreClinData/Melanoma/Breast – Moffitt/S.Antonia, UTSW/R.Brekken, UC-Irvine/CW.Hughes, Peregrine http://tinyurl.com/n7e7r7p
4-2014 AACR'14: Peregrine's 3 preclin. posters http://tinyurl.com/k4fl8z6 
...about Bavi as an “Upstream PS Checkpoint Inhibitor”; notably, “when combined with downstream immune checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1, PS targeting mediates an improved protective tumor-specific immunity following tumor rechallenge”, and, “combination of bavituximab with the anti-PD-1 checkpoint blockade should synergistically induce potent long-lasting antitumor immunity.”
4-2013 AACR'13: Peregrine's 3 preclin. posters http://tinyurl.com/cnqx9oh
..."data on the immune stimulating moa of Bavi, anti-tumor & imaging potential of other PS-targeting constructs"
BAVITUXIMAB ANTI-CANCER NEWS - Archive 2010-2012: http://tinyurl.com/y9t456ku
BAVITUXIMAB ANTI-CANCER NEWS - Archive 2004-2009: http://tinyurl.com/6pjqt27

IMAGING APPLICATIONS Of PS-TARGETING MABS:
10-2017/Mol-Imag: Results of Human Testing (n=11) of 124I-PGN650 PET Imaging http://tinyurl.com/y9ofyu8o
...”Tumor targeting in Pts was less than prev. observed in animal studies… tumor uptake was quite low & not sufficient for clinical studies.”
5-25-16/OncoTarget, “PS-Targeted Liposome [PGN635=Fhu-Bavi] For Enhanced Glioma-Selective Imaging” - Wake Forest's Dawen Zhao & UTSW's Liang Zhang http://tinyurl.com/z6lzkqm
6-2014: Two Bavi-Imaging abstracts by UTSW at Society of Nuclear Med+Molecular Imaging (SNMMI) Annual Mtg http://tinyurl.com/kemdu2d
11-26-13: PGN635 (Fhu-Bavi) Imaging article in Molecules2013 by UTSW’s Liang Zhang & Dawen Zhao http://tinyurl.com/mxzodta
12-19-13/PLOS/Philip Thorpe: “Highly Specific PET Imaging of Prostate Tumors in Mice with an Iodine-124-Labeled Antibody Fragment That Targets PS”  https://doi.org/10.1371/journal.pone.0084864
ANTI-PS IMAGING - Archive 2006-2012: http://tinyurl.com/ycteg9f8


OCULAR APPLICATIONS Of PS-TARGETING MABS:
11-1-15-UTSW/Mayo/Tulane/PRC: “PS-Targeting Mabs Inhibit Choroidal Angiogenesis InVivo & ExVivo” [CNV/Macular Degen] http://www.ncbi.nlm.nih.gov/pubmed/26529048
5-2012: Two Anti-PS (PGN632 + PGN635) Ocular posters at ARVO'12 Annual Mtg./FtLaud http://tinyurl.com/cax9a4p
..5-6-12/Thorpe+Mayo, "Anti-PS (PGN632 & PGN635) as Potential New Therapy Against Choroidal Neovascularization (CNV) - AMD"
..5-10-12/PPHM+LSU, "Efficacious Clinical Outcome of an Ophthalmic Formulation of PS-binding mab (PGN632) in a Rabbit Model of Acute HSV-1 Keratitis"


4 COMPLETED BAVITUXIMAB HEP-C PHASE1+2 TRIALS (2005-2011):
These 4 completed Ph.1/2 Bavi HCV Trials archived to: http://tinyurl.com/ycclu974
4. Phase II Bavi+Riba vs. Frontline-HEPC (randomized, open-label - 2011)
3. Phase 1B HCV-HIV Co-Infected's Mono Repeat-Dose Trial (2007-2011)
2. Phase 1B Bavi/Mono Repeat-Dose HCV Trial: (init=6-2006 comp=1-2007 n=24)
1. Phase 1A Bavi/Mono Single-Dose HCV Trial: (init=8-2005 comp=2-2006 n=30)


BAVITUXIMAB ANTI-VIRAL NEWS:
THESE 3 ANTI-VIRAL SECTIONS ARCHIVED 11-2017: http://tinyurl.com/y9t456ku
I. The 2008-2011 DTRA/TMT GOV'T CONTRACT FOR ANTI-PS VS. HEMORRHAGIC FEVERS
...Also see 3-2012 Earlier Archive of 2008-2011 DTRA Gov't Contract: http://tinyurl.com/6pjqt27
II. THE DUKE/HAYNES/CAVD/GATES/CHAVI/NIAID HIV COLLABORATION
...Also see 3-2012 Earlier Archive of Duke-PPHM-Chavi-Cavd HIV Collaboration: http://tinyurl.com/6pjqt27
III. OTHER ANTI-PS ANTI-VIRAL NEWS
...Also see 3-2012 Earlier Archive of Other Anti-Viral News (2005-2008): http://tinyurl.com/6pjqt27


TUMOR NECROSIS THERAPY (TNT/COTARA/VEA's) NEWS:
This defunct 1998-2012 pgm. archived to: http://tinyurl.com/yc4ye6m4

AFFITECH-PPHM Collab: Fully-Human Mabs, Anti-PS & Anti-VEGF/2C3
This defunct 2005-2012 pgm. archived to: http://tinyurl.com/yc4ye6m4

Dr. Phillip Thorpe Discusses BAVITUXIMAB at 2004 ASM (Bavi was formerly brand-named "Tarvacin"):
10-25-04 SHM Presentation: "Understanding Tarvacin", incl. his first-ever public comments about Tarvacin's ANTI-VIRAL capabilities:
"OK, this is Tarvacin.. the cleanest tumor vessel marker of which we are aware.. If you look here at the 3G4 slide, you'll see, most remarkably, that it's absolutely chock full with macrophages; they're beginning to outnumber the tumor cells... . So, the conclusions with Tarvacin are that it has a unique mechanism of action, there's nothing else like it out there; it homes specifically to tumor blood vessels and induces white blood cells to attack the tumor." http://tinyurl.com/38qjug

Dr. Thorpe's APT (AntiPS/3G4/BAVITUXIMAB patent app #20040161429 (pub. USPO 8-19-04):
"Compositions for treating Viral Infections using Immunoconjugates to Aminophospholipids": http://tinyurl.com/6pdny
[1302] "the 3G4 antibody has enormous potential as a broad spectrum anti-viral agent."
[1303] "...The inhibitory activities of 3G4 on cell division, angiogenesis, tumor growth & viral infectivity, taken together with lack of apparent toxicity, show broad therapeutic indications for this antibody, including in the treatment of angiogenic disorders, cancer, diabetes and viral infections."
[0196] "the anti-viral methods and uses of the invention are suitable for treating all viruses... as exemplified by treating CMV, RSV, arenavirus and HIV infections, and the diseases hepatitis, influenza, pneumonia, Lassa fever and AIDS."
[1298] "The 3G4 antibody has also been administered to monkeys in safety studies and no side effects have been observed."

The Inventor of the PS-Targeting Mabs, like 3G4/bavituximab, is Dr. Philip E. Thorpe of UTSW-MC/Dallas.
4-2-13: Peregrine Mourns Loss of Dr. Philip E. Thorpe (1951-2013) http://tinyurl.com/l9gqmt5
…2013: Dr. Thorpe’s lab taken over by UTSW’s Dr. Rolf A. Brekken: http://www.utsouthwestern.edu/labs/brekken
Dr. Thorpe's Patents: GRANTED: http://tinyurl.com/m232k PENDING: http://tinyurl.com/845p2
…Dr. Thorpe's Articles: http://tinyurl.com/csjsl Also see: http://www.researchgate.net/profile/Philip_Thorpe
Dr. Brekken’s Patents: GRANTED: http://tinyurl.com/q2joy3v PENDING:   http://tinyurl.com/l5jngmw
…Dr. Brekken’s Articles: http://tinyurl.com/oyf5r9p Also see: http://www.researchgate.net/profile/Rolf_Brekken
Dr. Alan Schroit's Patents (MDA/UTSW, PPHM SAB, “Clipped B2GP1”, PS-Exosomes): GRANTED: http://tinyurl.com/ybgvaf4g PENDING: http://tinyurl.com/yadltu9n
…Dr. Schroit’s Articles: http://tinyurl.com/lqbd8kt Also see: http://tinyurl.com/yaqnvcvq (UTSW profile)


PPHM BOARD RULES: http://tinyurl.com/zx2qa  - DISCLAIMER: This msg board is not affiliated with Peregrine; no endorsement by Peregrine or any other org. is implied.

SureTrader
CDMO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CDMO News: Peregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development a... 01/05/2018 08:05:00 AM
CDMO News: Peregrine Pharmaceuticals to Present at Biotech Showcase 2018 01/02/2018 08:05:00 AM
CDMO News: Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer 12/26/2017 08:05:00 AM
CDMO News: Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments 12/11/2017 04:05:00 PM
PostSubject
#323075  Sticky Note 1-18-18/2017 ASM: Roger Lias’ Slideshow & Attendee Reports cjgaddy 01/19/18 03:48:27 PM
#321884  Sticky Note 1-8-18: Name=>AVID, Tickers=CDMO/CDMOP, History of CDMO Transition cjgaddy 01/05/18 10:20:00 AM
#320583  Sticky Note 12-11-17 Qtly CC-Transcript, PR(Fin’s Q2FY18/qe10-31-17), Avid Revs History Table cjgaddy 12/12/17 02:32:53 PM
#303699  Sticky Note 7-14-17: Updates on the PS Exosomes Diagnostic Platform cjgaddy 07/15/17 04:27:09 PM
#298792  Sticky Note Sunrise Biomarkers (#1/B2GPI #2/COMPL,IL10 #3/IFN-y #4/PD-L1) – updated cjgaddy 06/06/17 12:10:40 PM
#294957  Sticky Note PPHM/MSKCC(Jedd Wolchok Lab) Collab: #1/Bavi+PD1+Rad, #2/Bavi+”ACT” cjgaddy 04/14/17 10:05:54 AM
#323171   goodJohn re potential in viral, such as HIV, swg_tdr 01/21/18 11:02:00 PM
#323170   simply staggering, the NON-INTEREST swg_tdr 01/21/18 10:45:58 PM
#323169   W.L. Gore is a very large, privately held north40000 01/21/18 10:03:52 PM
#323168   Nearly impossible becomes possible with sequencing biopharm 01/21/18 09:56:23 PM
#323167   phosphatidylserine is ubiquitous, and yet, targeting and exposing goodJohnhunting 01/21/18 09:42:03 PM
#323166   Consider who's mouth spouted those words ...lyttle is Bluerinse 01/21/18 09:27:48 PM
#323165   You are viewing the new design. Leave feedback biopharm 01/21/18 08:58:27 PM
#323164   yes. they went big with 22k shares. revenue_monster 01/21/18 08:49:45 PM
#323163   Another phrase contained in the ASM notes: "there's shipbuilder 01/21/18 08:23:32 PM
#323162   This was back from 2015 when these "new" biopharm 01/21/18 08:19:26 PM
#323161   There was a reference to consultants being involved shipbuilder 01/21/18 08:16:31 PM
#323160   "he is occupying his time acting as a patientlywaiting 01/21/18 08:14:25 PM
#323159   Hopefully BeiGene backers are in talks with Steve biopharm 01/21/18 07:45:15 PM
#323158   That is interesting as I have mentioned. What geocappy1 01/21/18 07:31:00 PM
#323157   #7 #8 PS Targeting Patent - Roche BMS biopharm 01/21/18 06:53:50 PM
#323156   JamesGMS, the image of 2017 AACR #1651 authored north40000 01/21/18 06:32:32 PM
#323155   The thought has occurred to me a few north40000 01/21/18 06:11:37 PM
#323154   if he’s as successful at peddling pphm platform revenue_monster 01/21/18 06:09:49 PM
#323153   When I asked PL at ASM what SK north40000 01/21/18 05:39:42 PM
#323152   BGNE: Like PRF, BGNE also accessed financing, even north40000 01/21/18 05:23:33 PM
#323151   ..PPHM will have to be very careful given biopharm 01/21/18 04:05:56 PM
#323150   Did we not get a picture, this year, shipbuilder 01/21/18 03:40:28 PM
#323149   Jerome Galon and Bernard Fox and gang....it is biopharm 01/21/18 03:26:56 PM
#323148   "....unless it is being saved for special Presidential situations" patientlywaiting 01/21/18 02:40:38 PM
#323147   Bernard Fox and Jerome Galon and gang all biopharm 01/21/18 02:28:02 PM
#323146   "The author has been made aware." patientlywaiting 01/21/18 02:21:11 PM
#323145   Absolutely right! So if I would read that Wernaaa 01/21/18 02:15:09 PM
#323144   no one on this board is privy to revenue_monster 01/21/18 02:09:31 PM
#323143   Jerome Galon biopharm 01/21/18 02:07:45 PM
#323142   Patientlywaiting, The author has been made aware. JamesGMS 01/21/18 02:03:47 PM
#323141   "If the author truly is not aware he patientlywaiting 01/21/18 01:45:08 PM
#323140   Hutschi, Very informative Car-T review. JamesGMS 01/21/18 01:34:12 PM
#323139   That means they fooled all shareholders and the Wernaaa 01/21/18 01:14:11 PM
#323138   John Silke biopharm 01/21/18 12:32:58 PM
#323137   has occurred to anyone that the new team revenue_monster 01/21/18 11:54:50 AM
#323136   I think that in the "Big Picture" BP patientlywaiting 01/21/18 11:50:35 AM
#323135   not only the "truth" but fire in their swg_tdr 01/21/18 11:10:05 AM
#323134   eb, you'd better get a deep pocket shareholder swg_tdr 01/21/18 11:06:01 AM
#323133   phosphatidylserine is ubiquitous, and yet, targeting and exposing ElSid18 01/21/18 11:03:10 AM
#323132   the general public doesn’t care about the does revenue_monster 01/21/18 09:29:15 AM
#323131   A Cure for Cancer? How CAR-T Therapy is hutschi 01/21/18 09:24:56 AM
#323130   Value of IP will also be reached by biopharm 01/21/18 08:43:35 AM
#323129   I would like to clarify something from my patientlywaiting 01/21/18 08:37:22 AM
#323128   Biopharm, I agree! When your letter is up atonewith PPHM 01/21/18 07:43:34 AM
#323127   I am mulling over the wording for my eb0783 01/21/18 12:30:47 AM
#323126   I would love to have Free the Mice epcjmc 01/21/18 12:21:15 AM
#323124   Thanks, EB! Hawkfan1 01/20/18 08:57:15 PM
#323123   When I said he will pay for his bfiest 01/20/18 05:40:54 PM
#323122   Great note taking and good posts hawkfan1! eb0783 01/20/18 05:39:15 PM
#323121   Essential question: If the IP has a value Wernaaa 01/20/18 05:01:51 PM
PostSubject